Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Combat Rising Medical Costs on First Party Auto Claims
Enlyte’s auto bill review solution reduced the medical bill by an average of 80%— so our customer pays 20 cents for every dollar charged.
Causes of Delayed Workplace Recoveries
Case managers can identify and address underlying behavioral health symptoms to keep workers' comp claims on track.
Not All PBMs are Created Equally: Examining the Differences Between Traditional Health Care and Workers’ Compensation PBM
Explore the key differences between healthcare and workers' compensation PBMs, and the unique regulatory challenges they face in this detailed analysis.
Technology aids workers comp claims advocacy
Implementing advanced technology and frontline patient advocacy are neck and neck among the fastest-growing trends in workers compensation claims management, but the best results for patients often come from balancing the two, experts say.
Diagnostic Imaging Services: Life of a Claim
View the Diagnostic Imaging Claims Process
Progressive Pathways: Exploring Workers’ Comp Legislation in Texas, New York, Illinois, California and Tennessee
Enlyte has seen a 12% increase in our Workers’ Compensation Professional Services Medical Price Index (MPI) since 2017, according to Michele Hibbert, Sr. VP of compliance. This divergence is unprecedented and significantly above the Consumer Price Index (CPI), which measures inflation across services/goods.